Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

Dongguan HEC Biopharmaceutical

Status and phase: Completed; Phase 2

Conditions: Type 2 Diabetes

Treatments: Drug: HEC88473, Placebo, Dulaglutide

Study type: Interventional

Funder types: Industry

Identifiers

NCT06148649

HEC88473-DM-201

Details and patient eligibility

About

This is a multicenter, randomized, parallel, placebo- and active comparator-controlled phase 2 trial to evaluate the efficacy, safety, pharmacokinetics and immunogenicity in subjects with T2DM.

Patients treated with diet and exercise alone, or in combination with stable metformin monotherapy (≥1500 mg/day or maximum tolerated dose ≥1000 mg/ day.), will be enrolled. Approximately 225 participants will be randomized. The study includes four stages: screening period (up to 2 weeks), lead-in period (2 weeks), treatment period (12 weeks) and safety follow-up period (3 weeks after treatment).

Enrollment: 234 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female patients 18 to 75 years of age, inclusive.
2. Have T2DM for at least 3 months before screening based on the disease diagnostic criteria (WHO 1999).
3. Have an HbA1c value of ≥7.5% and ≤10.5%, fasting blood-glucose ≤13.9 mmoL/L, at screening and visit 3.

Exclusion criteria

1. Have type 1 diabetes mellitus.
2. Have had ≥1 episode of severe hypoglycemia within 6 months before screening, or history of recurrent hypoglycemia (history of hypoglycemia more than 3 times in 3 months).
3. Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level >2.5 times the upper limit of the reference range at screening.
4. Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) at screening.
5. Have serum calcitonin ≥20 ng/L at screening.
6. Fasted triglycerides > 5.7 mmol/L at screening.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

234 participants in 5 patient groups, including a placebo group

HEC88473 dose1

Experimental group

Description:

T2DM subjects, receiving a weekly dose of HEC88473 dose1

Treatment:

Drug: HEC88473, Placebo, Dulaglutide

HEC88473 dose2

Experimental group

Description:

T2DM subjects, receiving a weekly dose of HEC88473 dose2

Treatment:

Drug: HEC88473, Placebo, Dulaglutide

HEC88473 dose3

Experimental group

Description:

T2DM subjects, receiving a weekly dose of HEC88473 dose3

Treatment:

Drug: HEC88473, Placebo, Dulaglutide

Placebo

Placebo Comparator group

Description:

T2DM subjects, receiving a weekly dose of placebo

Treatment:

Drug: HEC88473, Placebo, Dulaglutide

Dulaglutide

Active Comparator group

Description:

T2DM subjects, receiving a weekly dose of dulaglutide

Treatment:

Drug: HEC88473, Placebo, Dulaglutide